Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is a San Diego-based, clinical-stage biopharmaceutical company founded in 2006 that develops novel antifungal therapies for life-threatening infections in immunocompromised patients, backed by approximately $198 million in venture financing led by Sofinnova and including Pfizer as a strategic investor.
- Company typePrivate
- Founded2006
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Amplyx Pharmaceuticals does
Amplyx Pharmaceuticals is a privately held clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Diego, California. The company develops innovative small-molecule therapies targeting debilitating and life-threatening fungal infections in patients with compromised immune systems, including those with cancer, transplant recipients, and other immunocompromised populations. Its core pipeline centers on novel antifungal agents — most prominently the fosmanogepix (APX001) class — designed to address invasive candidiasis, aspergillosis, and rare mold infections where resistance to existing therapies is growing and mortality remains high.
The business operates as a venture-backed R&D organization. Across nine disclosed financing rounds from 2008 through May 2020, Amplyx has raised approximately $198 million from a syndicate led by Sofinnova Investments, RiverVest, 3x5 Special Opportunity Fund, and including New Enterprise Associates, Arix Bioscience, Lundbeckfonden Ventures, BioMed Ventures, Pappas Capital, Generation Ventures, Adage Capital Management, Pfizer, Keiretsu Forum, and TCA Venture Group. The May 2020 round notably included Pfizer as a strategic investor, creating a credible channel-to-market pathway given Pfizer's hospital anti-infective infrastructure.
The company has 11–50 employees organized around clinical development, program management, and operations. Leadership is concentrated in experienced anti-infective developers, including President & CEO Mike Grey, COO Christopher LeMasters, and senior clinical/development officers Carlos Sattler, Kevin Holme, and Pamela Wedel. Amplyx has no marketed products, no disclosed revenue, and operates as a pre-commercial entity; revenue mechanics are entirely prospective and contingent on regulatory approval, with potential pathways including direct commercialization, partnership, or acquisition by a large pharmaceutical company.
Amplyx Pharmaceuticals firmographics
Firmographics- Name
- Amplyx Pharmaceuticals
- Website
- https://amplyx.com
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 11–50 employees
- Short description
- Amplyx Pharmaceuticals is a San Diego-based, clinical-stage biopharmaceutical company founded in 2006 that develops novel antifungal therapies for life-threatening infections in immunocompromised patients, backed by approximately $198 million in venture financing led by Sofinnova and including Pfizer as a strategic investor.
- Ownership category
- akta.pro rank
Amplyx Pharmaceuticals industry classification
Industry- Product category
- Infectious Disease Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Transplant & Immunosuppression Specialty Pharmaceuticals (HLAIACAJ)
Keywords
Where Amplyx Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Amplyx Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Amplyx Pharmaceuticals product offering
Product offeringCore offering
Amplyx Pharmaceuticals develops innovative small-molecule therapies for debilitating and life-threatening diseases, with a primary focus on treating invasive fungal infections in patients with compromised immune systems. The company operates as a clinical-stage biopharmaceutical firm advancing novel antifungal drug candidates through preclinical and clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- Antifungal therapy pipeline (innovative therapies for immunocompromised patients)
Companies that use Amplyx Pharmaceuticals
Customer profileIdeal customer profiles1 record
Amplyx Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Amplyx Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Amplyx Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Global pharmaceutical company with an established anti-infective franchise (including antifungals and the source of Amplyx's expanded access connection). Acts as both an investor and a potential strategic acquirer; comparable as a broad incumbent in the anti-infective space.
- Astellas Pharma: Global pharmaceutical company with a leading antifungal franchise (Cresemba/isavuconazole) widely used in immunocompromised patients. Comparable as a large incumbent with overlapping anti-infective assets and relevant commercial reach.
Direct peers
- Cidara Therapeutics: Clinical-stage biotechnology company developing antifungal and antiviral therapies, including treatments for invasive fungal infections in immunocompromised patients. Directly comparable in indication focus, modality, and patient population.
- Scynexis: Developer of antifungal therapies (ibrexafungerp) targeting serious and life-threatening fungal infections, including in immunocompromised patients. Comparable in therapeutic area, clinical-stage profile, and patient population.
- F2G: Late-stage biopharmaceutical company developing novel therapies for invasive fungal infections, particularly in immunocompromised patients with limited treatment options. Direct antifungal-focused peer with similar unmet-need positioning.
- Basilea Pharmaceutica: Swiss biopharmaceutical company with a commercialized antifungal franchise (Cresemba) and a pipeline in serious bacterial and fungal infections. Comparable as a focused anti-infective specialist with both development and commercial-stage assets.
- Melinta Therapeutics: Commercial-stage anti-infective company with marketed antibiotics for serious and life-threatening infections. Comparable as a focused infectious disease company addressing hospitalized and immunocompromised patient populations.
- Paratek Pharmaceuticals: Commercial-stage biopharmaceutical company developing and commercializing antibiotics for serious community-acquired infections. Comparable as an infectious disease-focused specialty company with similar development and commercialization dynamics.
- Nabriva Therapeutics: Biopharmaceutical company developing anti-infective agents for serious and difficult-to-treat infections. Comparable as a development-stage anti-infective specialist addressing similar hospital and immunocompromised patient use cases.
- Viamet Pharmaceuticals: Clinical-stage biopharmaceutical company developing novel antifungal agents using metalloenzyme inhibitors. Comparable as a development-stage antifungal specialist targeting invasive fungal infections.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Amplyx Pharmaceuticals social profiles
Digital presenceAmplyx Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amplyx Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Amplyx Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amplyx Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amplyx Pharmaceuticals
What does Amplyx Pharmaceuticals do?
Amplyx Pharmaceuticals develops innovative small-molecule therapies for debilitating and life-threatening diseases, with a primary focus on treating invasive fungal infections in patients with compromised immune systems. The company operates as a clinical-stage biopharmaceutical firm advancing novel antifungal drug candidates through preclinical and clinical development.
When was Amplyx Pharmaceuticals founded?
Amplyx Pharmaceuticals was founded in 2006. It employs 11 to 50 people.
Where is Amplyx Pharmaceuticals based?
Amplyx Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
Who are Amplyx Pharmaceuticals's main competitors?
Broad incumbents on record are Pfizer and Astellas Pharma. Direct peers are Cidara Therapeutics, Scynexis, F2G, Basilea Pharmaceutica, Melinta Therapeutics, Paratek Pharmaceuticals, Nabriva Therapeutics and Viamet Pharmaceuticals.
Does Amplyx Pharmaceuticals have an API?
No public API is recorded for Amplyx Pharmaceuticals.
What industry is Amplyx Pharmaceuticals in?
Amplyx Pharmaceuticals's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.